Join to View Full Profile
13230 Dime Box TrlAustin, TX 78729
Phone+1 512-335-1584
Are you Dr. Schultz?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Kenneth Schultz, MD is an emergency medicine physician in Austin, Texas. He is currently licensed to practice medicine in Texas, California, and Pennsylvania.
Education & Training
Allegheny Health Network Medical Education Consortium (SVH)Residency, Family Medicine, 1999 - 2002
Texas Tech University Health Sciences Center School of MedicineClass of 1999
Certifications & Licensure
CA State Medical License 2003 - 2026
TX State Medical License 2003 - 2025
PA State Medical License 2000 - 2006- PA State Medical License 2000 - 2006
Grant Support
- Development of a novel, targeted small molecule inhibitor of the nucleoside salvage pathway through IND enabling studies and translational mouse models for acute disseminated encephalomyelitis (ADEM)TRETHERA CORPORATION2024–2026
- Development of a novel, targeted small molecule inhibitor of the nucleoside salvage pathway through IND enabling studies and translational mouse models for acute disseminated encephalomyelitis (ADEM)TRETHERA CORPORATION2024–2026
- Development of a novel, targeted small molecule inhibitor of the nucleoside salvage pathway through IND enabling studies and translational mouse models for acute disseminated encephalomyelitis (ADEM)TRETHERA CORPORATION2024–2026
- Development of a novel, targeted small molecule inhibitor of the nucleoside salvage pathway through IND enabling studies and translational mouse models for acute disseminated encephalomyelitis (ADEM)TRETHERA CORPORATION2024–2026
- Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleoside Salvage Pathway to Treat Optic NeuritisTRETHERA CORPORATION2022–2026
- Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleoside Salvage Pathway to Treat Optic NeuritisTRETHERA CORPORATION2022–2026
- Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleoside Salvage Pathway to Treat Acute Disseminated Encephalomyelitis (ADEM)TRETHERA CORPORATION2023–2025
- Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleotide Salvage Pathway to Treat Underserved Tumor TypesTRETHERA CORPORATION2023–2025
- Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleoside Salvage Pathway to Treat Acute Disseminated Encephalomyelitis (ADEM)TRETHERA CORPORATION2023–2025
- Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleoside Salvage Pathway to Treat Acute Disseminated Encephalomyelitis (ADEM)TRETHERA CORPORATION2023–2025
- Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleoside Salvage Pathway to Treat Acute Disseminated Encephalomyelitis (ADEM)TRETHERA CORPORATION2023–2025
- Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleoside Salvage Pathway to Treat Systemic Lupus ErythematosusTRETHERA CORPORATION2023–2025
